LB Pharma publishes positive Phase 2 LB-102 schizophrenia trial results in JAMA Psychiatry

• LB Pharmaceuticals published Phase 2 NOVA-1 trial results for once-daily oral LB-102 in JAMA Psychiatry; findings were first presented in early 2025.
• Trial showed LB-102 improved symptoms versus placebo, with rapid onset and sustained benefit through study end.
• Safety profile was described as favorable, with low rates of movement-related side effects, minimal sedation, and limited gastrointestinal issues.
• Pivotal Phase 3 NOVA-2 trial in acute schizophrenia is ongoing; topline results expected in second half of 2027.
• NOVA-2 is designed to enroll about 460 patients across 25 US sites, positioning LB-102 for a pre-NDA FDA meeting if results are positive.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604221605PRIMZONEFULLFEED9695089) on April 22, 2026, and is solely responsible for the information contained therein.